Tilray Brands, Inc. (2HQ.DE)
EUR 0.39
(-4.85%)
EUR 0.39
(-4.85%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -174.74 Million USD | 92.97% |
| 2022 | -1.36 Billion USD | -993.5% |
| 2021 | 153.29 Million USD | 3198.75% |
| 2020 | -4.94 Million USD | -109.61% |
| 2019 | 51.48 Million CAD | 2080.58% |
| 2018 | -2.59 Million CAD | 73.03% |
| 2017 | -9.63 Million CAD | -832.8% |
| 2016 | -1.03 Million CAD | -23.56% |
| 2015 | -836.22 Thousand CAD | 69.39% |
| 2014 | -2.73 Million CAD | -105.16% |
| 2013 | -1.33 Million USD | -2837.41% |
| 2012 | -45.33 Thousand CAD | 53.98% |
| 2011 | -98.51 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -36.57 Million USD | 61.81% |
| 2023 Q1 | -34.36 Million USD | 61.81% |
| 2023 Q4 | -6.3 Million USD | 92.32% |
| 2023 Q3 | -82.09 Million USD | -96.6% |
| 2023 FY | -96.33 Million USD | 92.97% |
| 2023 Q2 | -41.75 Million USD | -21.53% |
| 2022 Q4 | -89.98 Million USD | 92.54% |
| 2022 FY | -1.36 Billion USD | -993.5% |
| 2022 Q3 | -1.2 Billion USD | -2648.08% |
| 2022 Q2 | -43.91 Million USD | -31.73% |
| 2022 Q1 | -33.33 Million USD | -112.41% |
| 2021 FY | 153.29 Million USD | 3198.75% |
| 2021 Q4 | 268.52 Million USD | 1962.12% |
| 2021 Q1 | -68.53 Million USD | 7.01% |
| 2021 Q3 | 13.02 Million USD | 123.81% |
| 2021 Q2 | -54.68 Million USD | 20.21% |
| 2020 Q3 | -53.61 Million CAD | -61.11% |
| 2020 Q2 | -33.27 Million USD | -309.91% |
| 2020 FY | -4.94 Million USD | -109.61% |
| 2020 Q4 | -73.69 Million USD | -37.46% |
| 2020 Q1 | 15.85 Million USD | 131.77% |
| 2019 Q2 | -7.19 Million USD | -340.87% |
| 2019 Q3 | 6.5 Million USD | 190.4% |
| 2019 Q4 | -49.89 Million USD | -866.94% |
| 2019 FY | 51.48 Million CAD | 2080.58% |
| 2019 Q1 | 2.98 Million USD | 119.76% |
| 2018 Q1 | -7.96 Million USD | -19.65% |
| 2018 FY | -2.59 Million CAD | 73.03% |
| 2018 Q4 | -15.12 Million USD | 77.73% |
| 2018 Q3 | -67.89 Million USD | -318.21% |
| 2018 Q2 | -16.23 Million USD | -103.69% |
| 2017 Q4 | -6.66 Million USD | -110.68% |
| 2017 FY | -9.63 Million CAD | -832.8% |
| 2017 Q3 | -3.16 Million USD | -255.04% |
| 2017 Q1 | 1.09 Million USD | -27.53% |
| 2017 Q2 | -890.51 Thousand USD | -181.24% |
| 2016 FY | -1.03 Million CAD | -23.56% |
| 2016 Q4 | 1.51 Million USD | 143.07% |
| 2016 Q1 | 601.82 Thousand CAD | 1734.07% |
| 2016 Q3 | -3.51 Million USD | -1070.05% |
| 2016 Q2 | 362.01 Thousand CAD | -39.85% |
| 2015 Q1 | -396.13 Thousand CAD | 12.0% |
| 2015 Q3 | -61.81 Thousand CAD | 82.6% |
| 2015 Q4 | -36.82 Thousand CAD | 40.42% |
| 2015 FY | -836.22 Thousand CAD | 69.39% |
| 2015 Q2 | -355.2 Thousand CAD | 10.33% |
| 2014 Q4 | -450.17 Thousand CAD | -20.78% |
| 2014 Q3 | -372.72 Thousand CAD | -5650.01% |
| 2014 Q2 | -6482.23 CAD | 22.05% |
| 2014 Q1 | -8316.12 CAD | 86.85% |
| 2014 FY | -2.73 Million CAD | -105.16% |
| 2013 Q3 | -47.23 Thousand CAD | -933.36% |
| 2013 Q4 | -63.26 Thousand CAD | -33.93% |
| 2013 Q1 | -7855.65 CAD | -73.67% |
| 2013 FY | -1.33 Million USD | -2837.41% |
| 2013 Q2 | -4571.06 CAD | 41.81% |
| 2012 Q1 | -13.65 Thousand CAD | 24.11% |
| 2012 Q2 | -20.45 Thousand CAD | -49.81% |
| 2012 Q3 | -13.33 Thousand CAD | 34.84% |
| 2012 FY | -45.33 Thousand CAD | 53.98% |
| 2012 Q4 | -4523.23 CAD | 66.07% |
| 2011 Q4 | -17.99 Thousand CAD | 72.63% |
| 2011 Q3 | -65.73 Thousand CAD | -1819.75% |
| 2011 FY | -98.51 Thousand CAD | 0.0% |
| 2011 Q2 | -3424.37 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| MPH Health Care AG | 15.7 Million EUR | 1213.025% |
| Apontis Pharma AG | -15.1 Million EUR | -1057.252% |
| Dermapharm Holding SE | 182.89 Million EUR | 195.544% |
| Evotec SE | -47.5 Million EUR | -267.83% |
| MERCK Kommanditgesellschaft auf Aktien | 3.6 Billion EUR | 104.842% |
| PharmaSGP Holding SE | 40.91 Million EUR | 527.103% |
| SynBiotic SE | -7.58 Million EUR | -2204.749% |